Copyright The Street
Maverick investor Cathie Wood has just done what she does best: stirring the stock market’s proverbial pot while maintaining her faith in innovation. ARK Invest’s Nov. 3 trade disclosure saw her shed $7.69 million worth of Palantir (PLTR), even after the defense AI poster-child posted superb Q3 earnings, sending its shares up 10% in five days. Year to date, Palantir stock has skyrocketed north of 170%, and it shot up 20% in the past month alone. At the same time, Wood doubled down on other conviction plays in Bullish and Beam Therapeutics, underscoring the fact that she’s betting big on the future, albeit a slightly different one. Why Wood trimmed Palantir after a blowout quarter Wood’s latest move, where she’s selling right after a win, may seem counterintuitive to most. If you’ve watched the ARK Invest chief long enough, you know the rhythm: She looks to trim the victors, fund the next wave, and keep the five-year thesis intact. So why would she lighten up on one of AI’s hottest names following another blowout quarter? Well, in her playbook, that isn’t hesitation but more about rotation, where she’s cashing in on a high, not calling a top. Cathie Wood’s recent Palantir moves: Nov. 3, 2025 – ARKK: Sold 38,338 shares ($7.69 million) right after Palantir’s strong Q3 earnings performance. Oct. 31, 2025 – ARKK: Trimmed 41,892 shares ($8.15 million) with the stock continuing to climb late in the week. Oct. 30, 2025 – ARKX: Dropped 19,954 shares ($3.9 million). Oct. 29, 2025 – ARKF, ARKK, & ARKW: Combined sale of about 21,600 shares ($4.1 million) with AI names running hot. Other notable ARK sells on Monday: Roku: Sold 21,793 shares worth about $2.31 million. Guardant Health: Cut 13,426 shares valued at roughly $1.25 million. Adaptive Biotechnologies: Offloaded 46,710 shares for about $810,885. Palantir’s Q3 earnings showing was almost too good Palantir hit it out of the park in Q3. Top- and bottom-line performances topped expectations again, as U.S. commercial activity kept ripping and guidance moved higher. CEO Alex Karp weighed in on Palantir’s smashing Q3 earnings, hailing the commercial business as an “absolute juggernaut” while describing overall growth as “otherworldly.” Fund manager buys and sells Cathie Wood sells $21.4 million of surging AI stocks Veteran fund manager sees quiet fuel for next AI rally Top analyst calls ‘kick in the pants’ for S&P 500 Additionally, Karp talked about how he isn’t selling the sizzle of AI, but the system. In Palantir’s Q3 call, he framed the businesses as less of a “model shop” and more of an operating system for decision-making, covering battlefields to boardrooms. Bootcamps have effectively become Palantir’s secret weapon, turning months of AI testing into production wins and generating a ton of cash. “We’re focused on time to value,” Karp said, pitching AI that works quickly and pays its own bills. Palantir Q3 by the numbers Beat and Raise: Revenue came in at $1.181 billion, up 63% year over year and 18% quarter over quarter. Adjusted EPS came in at $0.21 (beating estimates by $0.04), while GAAP EPS was $0.18. Margins and free cash flow: Adjusted operating margin stood at 51%, with GAAP at 33%. Adjusted free cash flow was $540 million, a hefty 46% margin. Raised guidance: Palantir lifted its full-year 2025 outlook to $4.396–$4.400 billion in sales, seeing Q4 at $1.327–$1.331 billion, blowing past Wall Street’s range. U.S. commercial on fire: U.S. commercial revenue soared 121% year over year to $397 million. Total U.S. revenue jumped 77% year over year to $883 million. Record deal flow: The company wrapped up 204 deals worth $1 million or more, driving total contract value (TCV) to $2.76 billion, up 151% year over year. U.S. commercial TCV alone hit $1.31 billion, up 342%. Customer count rose 45% year over year. Rule of 40 = 114%: For context, the Rule of 40 combines revenue growth along with profit margin, with anything above 40% signaling balanced, high-quality growth. Palantir’s 114% score screams “profitable hypergrowth.” Where Wood’s conviction is heading next Though the Palantir trim grabbed the headlines, Wood is already redeploying into digital assets along with biotech, as she plays offense in a market that still loves defense. She’s been saying the quiet part out loud on health care AI: “The most profound application of AI is in health care… This is the sleeper. It’s the most inefficiently priced part of the market.” Moreover, ARK’s own models support the pivot in that digital wallets could potentially capture 72% of e-commerce by 2030, with AI “purchasing agents” generating $40–$200 billion in global sales. Loading up on Bullish and Beam Wood didn’t just trim; she reloaded, too. ARK scooped up 238,346 shares of Bullish stock across ARKK, ARKW, and ARKF valued at about $12.05 million, the second Bullish buy in a week, highlighting a growing conviction in digital finance. Bullish isn’t your normal crypto play; it’s a regulated, institutional trading platform that’s looking to make digital asset trading a lot smoother and safer. Its splashy August NYSE debut saw the stock open at $37 and rocket to $118, cementing it as arguably 2025’s most-watched fintech story. On the biotech side, Wood added 336,257 shares of Beam Therapeutics ($8.4 million), known as a pioneer in base editing. This next-gen gene-editing approach is a bet on medicine that edits the disease at its source, instead of just treating it.
